fda glp-1 compounding warning october 2025 is short-sighted on GLP-1s Beyond the Headlines: FDA Warning

Sinha, R., Sinha, I., Calcagnotto, A., Trushin, N., Haley, J.S., Schell, T.D., and Richie, J.P

Subsequent dose adjustments may be made based on how your body responds to the medication, typically with another increase after an additional four weeks under medical supervision

Therefore, the efficacy and safety of GLP-1 RMs for use in dumping syndrome, despite the enabling theoretical physiological basis for these medications, remains poorly characterised

The safest response is not to begin with graft numbers or a choice between follicular unit excision (FUE) and follicular unit transplantation (FUT)

The secondary outcomes will assess other biomarkers linked to insulin transportation, such as changes in serum GIP (gastric inhibitory polypeptide), DPP-4, glucagon, glucose, and insulin levels